Acer Therapeutics Inc (ACER) Actualités

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals

NEWTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEFM14A - Definitive proxy statement relating to merger or acquisition

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product

Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra’s purchase...

Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe

NEWTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

NEWTON, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical...